MyFinsight
Home
Blog
About
Contact
Proceeds from sale of
revenue participation...
$200,000K
Proceeds from
underwriter exercising...
$12,366K
Proceeds from exercise of
awards under equity...
$6,695K
Maturities and sales of
marketable securities
$220,000K
Net cash provided by
(used in) financing...
$219,044K
Net cash provided by
investing activities
$94,460K
Canceled cashflow
$17K
Canceled cashflow
$125,540K
Net increase
(decrease) in cash, cash...
$182,300K
Canceled cashflow
$131,204K
Payments for finance
lease right-of-use...
$17K
Stockbased compensation
expense
$23,087K
Accounts payable
$3,875K
Depreciation and
amortization
$2,845K
Right-of-use asset
amortization for finance...
$916K
Other non-cash items
-$294K
Purchases of marketable
securities
$123,074K
Purchases of property and
equipment
$2,466K
Net cash used in
operating activities
-$131,204K
Canceled cashflow
$31,017K
Net loss
-$128,447K
Accruals and other
current liabilities
-$22,395K
Deferred research and
development funding...
-$5,985K
Prepaid expenses and
other current assets
$2,291K
Net accretion of
discounts on marketable...
$1,259K
Non-cash adjustment to
operating lease expense
$1,144K
Other non-current
assets
$700K
Back
Back
Cash Flow
Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI)
source: myfinsight.com